Board summary
Key figures
67,048
Registered population
61.8% aged 18–64
19.1%
Aged 65+
ICB 19.0% · England 17.9%
7.5%
Ethnic minority (non-White)
4.0% Asian · England 9.6%
21.5%
In IMD quintile 1
ICB 31.9% · England 21.0%
~12,435
Core20 residents (est.)
Resident basis; registered basis ~17,288 · see page 3
11,392
Hypertension register
+6.74% in 3 yrs · England +5.60%
763
SMI register
34.3% of Warrington (LAD)'s
1,350
COPD register
Reviews +5.73% in 3 yrs
Forecast to 2030
13,063
Hypertension patients, 2030
+1,671 on today
59.0%
QRISK ≥20% on statins, 2030
-3.63pp over 3 yrs
4.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
High-risk lipid therapy fell over three years.
QRISK ≥ 20% lipid therapy fell 5.2% over 2023 to 2025 (England +6.2%) to 65.7%, which may reflect unverified recall gaps.
Heart failure functional reviews trail England.
Annual heart failure functional reviews sit at 71.0% (England 78.5%) after falling 1.6% over 2023 to 2025 against England's +8.7% rise.
Asthma review coverage rose sharply since 2023.
Annual asthma reviews rose +37.6% over 2023 to 2025 (England +4.4%) to 67.7%, though about 1,400 registered patients still lack a recorded review.
Population, age and ethnicity
Patients aged 65+ make up 19.1% of the list alongside 32 catchment care homes
The PCN registers 67,048 patients across seven practices. Of registered patients, 19.1% (12,799 patients) are aged 65+, compared to 17.5% in Warrington (LAD), 19.0% in NHS Cheshire and Merseyside ICB, and 17.9% in England. Projected list growth to 2030 is 0.3% (Warrington (LAD) 0.7%, ICB 2.3%, England 2.3%; methodology unverified). By Census usual resident estimates, 92.5% are White (England 81.1%) and 4.0% are Asian or Asian British (Warrington (LAD) 3.3%, England 9.6%), reaching 8.6% at Dallam Lane Medical Centre.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Warrington (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Warrington LA) | 1,737 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.7% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Warrington LA) | 905 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Warrington LA) | 12.1 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation is moderate overall but masks a 53.3 pp practice divide
Average IMD is decile 6.2 and Core20 prevalence is 21.5%, above Warrington (LAD) (16.9%) and England (21.0%). Across practices, Core20 share spans 53.3 pp, from 53.3% at Dallam Lane Medical Centre to 0.0% at Penketh Health Centre. Estimated Core20 volume is highest at The Eric Moore Partnership (6,363 patients) and Folly Lane Medical Centre (4,743 patients). Practice-weighted registered estimates total 17,288 patients (25.8% share), diverging from 12,435 resident patients in deciles 1 and 2. Different denominator bases require reconciliation before deploying targeted outreach.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
763
SMI register
1.12% recorded prevalence
410
Learning disability register
0.60% recorded prevalence
32
Care homes, 1,289 beds
In the PCN catchment
9.4%
Provide unpaid care
Warrington (LAD), Census 2021
The PCN records 763 patients on the severe mental illness register (1.1% prevalence) and 410 on the learning disability register (0.6%), alongside 32 catchment care homes (1,289 beds). Borough context includes 9 people sleeping rough in the 2025 autumn snapshot and an estimated ceiling of 6,303 unpaid carers (applying the 9.4% borough rate), neither of which represents a registered PCN count.
Severe mental illness: physical health checks
Recorded SMI prevalence is 1.1%. Annual checks reached 85.6% for blood pressure and 86.6% for BMI, but three-year blood pressure check growth (+1.1 pp) lagged England (+4.4 pp), which could indicate slowing physical health check momentum.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
11,392
Hypertension register
+6.74%
Register growth, 3 yrs
Warrington (LAD) +6.41% · England +5.60%
+1.98pp
BP control, under 80
≤140/90 · +0.05pp aged 80+
+1,671
More patients by 2030
Forecast 13,063 (19.11%)
Hypertension case-finding and control
Hypertension register prevalence is 16.8% (11,392 patients), compared to 16.4% in Warrington (LAD), 16.8% in NHS Cheshire and Merseyside Integrated Care Board, and 15.2% in England. Among diagnosed patients, 70.5% are treated to target, which is in line with England (70.3%) and above the borough (68.7%). However, recent blood pressure recording reaches 86.2%, matching the borough (86.2%) but trailing England (90.0%) and the ICB (88.3%), despite a three-year rise of +4.3% (+3.6% in England). Observation periods were not supplied for current prevalence figures. Blood pressure recording trails national levels, which may leave unmonitored hypertensive patients at risk of uncontrolled disease and prioritises systematic annual recall.
Lipids and statins
Lipid-lowering therapy coverage for patients with QRISK ≥ 20% is 65.7%, exceeding England (63.6%) and Warrington (LAD) (61.6%). However, coverage fell 5.2% over 2023 to 2025 (England +6.2%). Three-year coverage trails national progress, which could suggest an emerging recall gap to investigate among high-risk patients.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 112,826 | £1.50 | £1.71 | £1.86 | £169,239 |
| Cardiovascular (all), 2025 | 155,972 | £5.37 | £4.37 | £3.33 | £837,570 |
For lipid-regulating drugs in 2026, PCN cost per item was £1.50 across 112,826 items, compared to £1.86 in England, £1.59 in Warrington (LAD), and £1.71 in the ICB. This is £40,617 less than at England's unit cost. Spending less than England's unit cost could offer prescribing headroom to prioritise expanding treatment reach to under-served high-risk cohorts.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+37.60%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.88%
Asthma prevalence, PCN 3-yr % change
Asthma reviews rose +37.6% (+18.5 pp) over 2023 to 2025 to 67.7% (England 65.7%), and COPD reviews reached 77.8% (England 76.4%). However, an estimated 1,382 asthma patients on the 4,280 register remain without a recorded review. Furthermore, recording of second-hand smoke exposure among asthma patients aged 6–19 stands at 75.8% (336 patients), trailing England (78.8%) by 3.0 percentage points. This gap suggests that younger respiratory cohorts may require targeted proactive review outreach.
Cancer register and children's immunisation
Recorded cancer prevalence is 3.9% (2,643 patients). For childhood immunisations, 24-month coverage is below the 95% coverage target by 4.9 pp for MMR dose 1 (90.1%) and by 3.5 pp for the 6-in-1 complete primary course (91.5%), with MMR dose 2 coverage at age 5 reaching 94.2%. Across captured practices, the range in QOF vaccination and immunisation-domain achievement is 73.5 pp. Folly Lane Medical Centre recorded 26.53%. Penketh Health Centre recorded 100.0%.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of staged cancers across NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2 (England 55.3%), sitting below the 75.0% national ambition by 19.5 percentage points. Closing this ICB gap requires about 2,640 extra early-stage diagnoses annually, with early presentation lagging below the ambition by 34.6 percentage points in lung (40.4%) and 30.1 percentage points in bowel (44.9%). In the PCN, 2,643 patients are on the cancer register (3.9%). Cervical screening coverage aged 25–49 is 70.5% overall, falling to 64.2% at Dallam Lane Medical Centre. Proactive screening recall in lower-coverage practices could help address local uptake variation.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), North Cheshire and Mersey NHS Foundation Trust achieved 83.7% against the 85.0% cancer 62-day referral to treatment standard, below the standard by 1.3 percentage points. It exceeded Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%), Manchester University NHS Foundation Trust (72.8%), NHS Cheshire and Merseyside Integrated Care Board (76.2%), and England (71.2%). The trust reached 80.2% on the 28-day faster diagnosis standard, exceeding the 75.0% standard, ahead of the ICB (77.2%) and England (79.3%). These metrics reflect trust rather than PCN performance.
| Pathways within standard (%) | North Cheshire and Mersey | Mersey and West Lancashire | Manchester | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.21 | 72.39 | 80.06 | 77.25 | 79.32 |
| 31-day treatment (96%) | 98.17 | 95.46 | 92.54 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 83.67 | 77.96 | 72.85 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | North Cheshire and Mersey | Mersey and West Lancashire | Manchester | England |
|---|---|---|---|---|
| MRI | 0.53 | 14.04 | 11.68 | 21.40 |
| CT | 2.32 | 13.08 | 14.66 | 9.92 |
| Echocardiography | 28.04 | 34.88 | 4.91 | 28.48 |
| Colonoscopy | 15.98 | 18.04 | 4.51 | 30.83 |
| Gastroscopy | 20.24 | 18.17 | 29.35 | 29.02 |
| All 15 DM01 tests | 6.34 | 21.17 | 8.98 | 23.14 |
| Community services activity | Warrington residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 38,550 | 541,280 |
| Referrals | 7,320 | 97,150 |
| Patients with a contact | 14,830 | 146,240 |
Community services (residents of Warrington), Jun 2026 (provisional). In June 2026 (provisional), Warrington borough residents accounted for 38,550 community service contacts. Adults aged 65 and over represented 56% of these contacts (21,595 contacts). These borough-level data reflect local demand for community services rather than PCN-level delivery.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Eric Moore | 113 | 50.6 | 67.4% | 73.1% | 82.3% |
| Causeway | 93 | 2.4 | 70.9% | 63.6% | 77.3% |
| Penketh | 104 | 0.0 | 44.1% | 70.5% | 77.2% |
| Dallam Lane | 96 | 53.3 | 78.9% | 87.8% | 76.5% |
| Helsby Street | 108 | 31.7 | 44.7% | 65.6% | 73.5% |
| Folly Lane | 93 | 50.1 | 31.3% | 66.4% | 70.2% |
| Westbrook | 106 | 5.5 | 40.6% | 73.2% | 67.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fourteen of 25 tracked measures trail England's three-year change, led by lipid therapy
Over 2023 to 2025, 14 of 25 tracked measures trailed England. The widest lags were QRISK ≥ 20% lipid therapy (-5.2% vs England +6.2%) and heart failure functional reviews (-1.6% vs England +8.7%). Severe mental illness alcohol recording (+2.0 pp vs England +5.4 pp) and blood pressure checks (+1.1 pp vs England +4.4 pp) also lagged. Conversely, asthma reviews rose +37.6% (England +4.4%) and smoking cessation offers rose +10.9 pp (England +0.1 pp). Prioritising recall audits on trailing cardiovascular and mental health pathways could recover lost ground.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
QRISK statin treatment
Heart failure reviews
Depression register
Dementia register
Alcohol record (psychosis)
Asthma reviews
Smoking support (SMI)
COPD reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Warrington (LAD) | Asset | PCN | Warrington (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 32 (1,289 beds) | n/a | Schools (catchment) | 99 | n/a |
| Children's centres | 7 | 12 | Places of worship | 49 | 89 |
| Libraries | 2 | 7 | Primary schools (LA maintained) | 17 | 28 |
| Primary academies | 17 | 31 | Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Heart failure register and review recall
Heart failure prevalence is 1.0% (699 patients vs Warrington (LAD) 1.1%, England 1.1%; modelled gap +37 to +68), while functional reviews (71.0% vs England 78.5%) fell 1.6% over 2023 to 2025 (England +8.7%). For discussion: run structured recall for annual functional assessments and audit records for uncoded heart failure. Moderate effort to run.
Option 2
Asthma review and youth smoke recall
Despite +37.6% growth to 67.7% (England 65.7%), an estimated 1,382 of 4,280 asthma patients lack a recorded review, and youth second-hand smoke recording is 75.8% (England 78.8%). For discussion: offer flexible review slots and check templates prompt second-hand smoke recording for ages 6 to 19. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
CVD lipid therapy and BP recall
QRISK ≥ 20% lipid therapy (65.7%) fell 5.2% (-3.6 pp; England +6.2%), recent BP checks (86.2%) trail England (90.0%), and 2025 CVD drug cost (£5.37) is £318,183 more than England's (£3.33) across 155,972 items. For discussion: run pharmacist-led lipid recall alongside annual BP checks for the 11,392 hypertension register. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally adapted access review (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Core20 list reconciliation and outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall audit (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure recall audit (p5) | Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood immunisation recall review (p6) | MMR dose 1 coverage at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Option 1 · Heart failure register and review recall (p12) | Heart failure register · Heart Failure: QOF prevalence · Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) | — | PCN |
| Option 2 · Asthma review and youth smoke recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · CVD lipid therapy and BP recall (p12) | Hypertension register · Hypertension patients with a recent BP reading · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
